Scorpius Holdings, Inc., a pharmaceutical company with a market capitalization of $1.36 million, has entered into a material definitive agreement through the issuance of a non-convertible ...

Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced its collaboration with KaloCyte, ...

Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programsDURHAM, N.C., Jan. 22, 2025 (GLOBE ...

Scorpius Holdings, Inc., a pharmaceutical company with a market capitalization of $1.36 million, has entered into a material definitive agreement through the issuance of a non-convertible promissory ...

Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO") ...

Scorpius Holdings, Inc. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art ...

DURHAM, N.C., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development ...

Scorpius Holdings, Inc. has announced a collaboration with KaloCyte to improve the manufacturing efficiency of KaloCyte's lead product, ErythroMer™, a bio-engineered artificial red blood cell ...

Scorpius announced its collaboration with KaloCyte. Under this initial project, Scorpius will utilize its scientific and technical expertise to ...